Important Update: The STING & TLR-Targeting Therapies Summit
With only a few weeks left to go, the STING & TLR-Targeting Therapies Summit has announced some exciting updates as the industry prepares for this definitive meeting.
Over 100 Attendees And Counting
100+ attendees have now confirmed their attendance at the summit this May 25-27.
So far, the likes of AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Checkmate Pharmaceuticals Daiichi Sankyo, Roche, GlaxoSmithKline, Highlight Therapeutics, Mersana Therapeutics, Pelago Bioscience, Primmune Therapeutics, Seven & Eight Pharmaceuticals, Tallac Therapeutics, Verseau Therapeutics and many more have secured their places.
Abbvie, BioNTech, Bolt Therapeutics, H3 Biomedicine, MD Anderson Cancer Center, Merck and Sutro Biopharma have also taken advantage of the group discounts, securing up to 20% off for their teams as well as a considerable presence at this important meeting.
They’ll all have access to exclusive content from the expert speaker faculty (also available post-event), plus they’ll partake in discussions and Q & As in order to hone their innate immune activation strategies and deliver safe and effective treatments through systematic and intra-tumoral administration which can stimulate the adaptive immune arm, counteract solid tumor-induced immunosuppression and increase response to checkpoint inhibitors.
View the full event guide here to see what will be discussed in full.
Exclusive Early Insights Available Now
“Preclinical and clinical data indicate the combination of the bacterial chassis and STING agonist results in target activation, durable inflammatory response, including infiltration of lymphocytes into the tumor, and an acceptable safety profile in doses tested to date.”
David Hava, Chief Scientific Officer at Synlogic will be discussing reprogramming the tumor microenvironment in his session on day two of the meeting. In an exclusive interview, he provided some early insight into how the engineered bacterial delivery of a STING agonist enabled Synlogic’s drug candidate, SYNB1891.
In total the meeting has released three detailed speaker interviews in anticipation of the meeting as the industry’s excitement builds.
Click here to view the full David Hava interview, as well as those with Art Krieg, Found & Chief Scientific Officer at Checkmate Pharmaceuticals, and Sonia Macia, Director, Medical at Highlight Therapeutics.
Four Event Partners Confirmed
As well as discussing the development of their STING & TLR targeting therapies, attendees to the meeting will also be able to meet with the events partners who could accelerate their research even further.
4D pharma plc is a biotech that’s leading the development of Live Biotherapeutic Products (LBPs), whilst Nilogen Oncosystems has developed the most clinically-relevant model of patient tumor biology using fresh human tumor tissue and paired it with a unique holistic platform of assays to help translational scientists make better decisions about their candidate therapies.
Meanwhile GenOway will be the onsite leader in the field of customized, genetically modified (GM) mouse, rat and cell model creation and intoDNA will be available to discuss their DNA direct damage detection technology.
View the event guide now to learn more about the event’s partners or partnership opportunities.
The Countdown is On!
Over 100 attendees, 67 organizations, 39 expert speakers, 5 weeks to go, 4 event partners, 3 days of content and only 1 more chance to secure tickets at a discounted rate.
Register before Friday, May 7 to save up to $200.
Find Out More:
View the full event guide here for more details about the speakers, agenda, digital platform and pricing.
Alternatively, contact the team using the details below.
And listen out for more updates on the digital STING & TLR-Targeting Therapies Summit!
Contact
General Enquiries & Registration Assistance
Rex Orcajada
Delegate Acquisition Manager
Hanson Wade
(+1) 617 455 4188
info@hansonwade.com
Partnership Opportunities
Jack Marcus
Partnerships Director
Hanson Wade
(+1) 617 455 4188
sponsor@hansonwade.com